SEC Comment Letter for VERTEX PHARMACEUTICALS (VRTX) — May 21, 2015
VERTEX PHARMACEUTICALS INC / MA (VRTX) (CIK 0000875320)
Date: May 21, 2015 · CIK: 0000875320 · Accession: 0000000000-15-027664
AI Filing Summary & Sentiment
Reasoning
Letter
May 21, 2015 Via E -mail Jeffrey M. Leiden President and Chief Executive Officer Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, Massachusetts 02210
Re: Vertex Pharmaceuticals Incorporated Form 10 -K for the Fiscal Year Ended December 31, 2014 Filed February 13, 2015 File No. 000 -19319
Dear Mr. Leiden:
We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person u nder the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Daniel Greenspan for
Show Raw Text
May 21, 2015 Via E -mail Jeffrey M. Leiden President and Chief Executive Officer Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, Massachusetts 02210 Re: Vertex Pharmaceuticals Incorporated Form 10 -K for the Fiscal Year Ended December 31, 2014 Filed February 13, 2015 File No. 000 -19319 Dear Mr. Leiden: We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person u nder the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Daniel Greenspan for Jeffrey P. Riedler Assistant Director